Pretransplant dialysis duration and risk of death after kidney transplantation in the current era

Transplantation

Volumn 98, Issue 4, 2014, Pages 458-464

  Helanterä, Ilkka ^a   Salmela, Kaija ^a   Kyllönen, Lauri ^a   Koskinen, Petri ^a   Grönhagen Riska, Carola ^a,b   Finne, Patrik ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Finnish Registry for Kidney Diseases   (Finland)

Author keywords

Dialysis; Kidney transplantation; Outcome

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; DEATH; END STAGE RENAL DISEASE; FEMALE; FINLAND; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; AGED; HOSPITAL ADMISSION; MIDDLE AGED; MORTALITY; RISK; TIME;

ADULT; AGED; FEMALE; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK; TIME FACTORS; WAITING LISTS;

EID: 84908010437     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000085     Document Type: Article

References (24)

1. Terasaki PI, Cecka JM, Gjertson DW, et al. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333.
2. Meier-Kriesche HU, Schold JD, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
3. Meier-Kriesche HU, Scornik JC, Susskind B, et al. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients. Transplantation 2009; 88: 23.
4. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388.
5. Helanterä I, Egli A, Koskinen P, et al. Viral impact on long-term kidney graft function. Infect Dis Clin North Am 2010; 24: 339.
6. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923.
7. Cosio FG, Alamir A, Yim S, et al. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 1998; 53: 767.
8. Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, et al. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant 2005; 20: 167.
9. Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311.
10. Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 2001; 344: 726.
11. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74: 1377.
12. Schold JD, Sehgal AR, Srinivas TR, et al. Marked variation of the association of ESRD duration before and after wait listing on kidney transplant outcomes. Am J Transplant 2010; 10: 2008.
13. Knoll G, Muirhear N, Trpeski L, et al. Patient survival following renal transplant failure in Canada. Am J Transplant 2005; 5: 1719.
14. Gondos A, Dohler B, Brenner H, et al. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 2013; 95: 267.
15. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med 2010; 363: 1833.
16. Foley RN, Hakim RM. Why is the mortality of dialysis patients in the United States much higher than the rest of the world? J Am Soc Nephrol 2009; 20: 1432.
17. Locatelli F, Canaud B. Dialysis adequacy today: a European perspective. Nephrol Dial Transplant 2012; 27: 3043.
18. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648.
19. Zoppellaro G, Faggin E, Puato M, et al. Fibroblast growth factor 23 and the bone-vascular axis: lessons learned from animal studies. Am J Kidney Dis 2012; 59: 135.
20. Frazao JM, Adragao T. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data. Kidney Int 2008; 74: S38.
21. Degenhardt TP, Grass L, Reddy S, et al. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997; 52: 1064.
22. Hall YN, Choi AJ, Xu P, et al. Racial ethnic differences in rates and determinant of deceased donor kidney transplantation. J Am Soc Nephrol 2011; 22: 743.
23. Joshi S, Gaynor JJ, Bayers S, et al. Disparities among Blacks, Hispanics, and Whites in time from starting dialysis to kidney transplant waitlisting. Transplantation 2013; 95: 309.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496.